“…For example, cancer cells have the higher level of ROS, whereas the level of ROS in normal cells at homeostatic conditions is negligible [ 16 , 17 , 18 ]. Known ROS activated prodrugs include N -alkylaminoferrocene-based (NAAF)-prodrugs [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ], pro-DNA alkylators [ 30 , 31 ], hydroxyferrocifens and their analogues [ 32 , 33 ], organochalcogen-based redox catalysts [ 34 ] and oligoferrocenes [ 35 ]. Unexpectedly, we have found that early NAAF prodrugs [ 18 , 19 , 21 ] exhibit no radiosensitizing effects (unpublished results) indicating that the intracellular ROS amplification alone is not sufficient to achieve the synergy with RT.…”